.Pharmacolibrary.Drugs.D_Dermatologicals.D06A_AntibioticsForTopicalUse.D06AX12_Amikacin.Amikacin .Pharmacolibrary.Drugs.D_Dermatologicals.D06A_AntibioticsForTopicalUse.D06AX12_Amikacin.Amikacin| name: | Amikacin |
| ATC code: | D06AX12 | route: | intravenous |
| n-compartments | 2 |
Amikacin is an aminoglycoside antibiotic used primarily for the treatment of severe bacterial infections caused by Gram-negative bacteria, including those resistant to other aminoglycosides. It is approved and commonly used today, mainly in hospital settings for serious infections such as sepsis, pneumonia, urinary tract infections, and intra-abdominal infections.
Pharmacokinetic parameters reported for adult patients with normal renal function receiving intravenous infusion.
Severino, N, et al., & Paredes, N (2023). Population pharmacokinetics of amikacin in suspected cases of neonatal sepsis. British journal of clinical pharmacology 89(7) 2254–2262. DOI:10.1111/bcp.15697 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36811146
Medellín-Garibay, SE, et al., & García, B (2022). Amikacin pharmacokinetics in elderly patients with severe infections. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 175 106219–None. DOI:10.1016/j.ejps.2022.106219 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35618200
Bressolle, F, et al., & Gomeni, R (1996). Population pharmacokinetics of amikacin in critically ill patients. Antimicrobial agents and chemotherapy 40(7) 1682–1689. DOI:10.1128/AAC.40.7.1682 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8807062